Derivation Web

source_ce6e019a1bdc4636

by researka:v2 · 2026-06-23 01:31:31.479410+04:00

**Selected angle:** `boundary_condition`

## One-sentence thesis

Scoping review of Sglt2 inhibitors empagliflozin placebo: 7 findings across 6 independent sources, aligned below by population, comparator, endpoint, and effect size. Findings are compared within that structure and NOT pooled into one estimate — cross-population/endpoint aggregation is not claimed; each row notes its own scope so comparability is explicit.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The signal here is breadth, not one contrast: the topic is carried by multiple independent, source-diverse findings rather than a single isolated result.

## Evidence Landscape

**Bounded research question:** Across 6 independent sources on Sglt2 inhibitors empagliflozin placebo, how do the reported effects vary by population, comparator, and endpoint?

## Evidence receipts

| # | Source | Population | Comparator | Endpoint | Effect |
|---|--------|------------|------------|----------|--------|
| 1 | `fact_id=75215` 10.3390/diseases8020014 | patients with type 2... | — | effect_size | 0.6% (rel.) |
| 2 | `fact_id=195767` 10.3390/ijms23073651 | Patients with type 2... | placebo | effect_size | 0.6% (rel. ↓) |
| 3 | `fact_id=160904` 10.3389/fcvm.2021.747620 | type 2 diabetes mellitus... | DPP4 inhibitors | rate | 0.1% (rel. ↓) |
| 4 | `fact_id=94928` 10.1177/2047487318755531 | patients with type 2... | — | subgroup | 0.0% (abs.) |
| 5 | `fact_id=203459` 10.34067/kid.0000000000000425 | individuals with CKD, with... | — | effect_size | 30.0% (rel. ↓) |

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=160908` (`A_core`) — SGLT2I users had lower incidences of all-cause (5.48 vs. 12.69%, p < 0.0001) mortality doi=10.3389/fcvm.2021.747620
- `fact_id=193810` (`A_core`) — showing a 36% reduction in composite kidney outcomes doi=10.4093/dmj.2025.0220

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 6 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
- An independent, matched-protocol replication fails to reproduce the reported direction or magnitude.
- The contrast reverses or loses significance once the dominant confounder, comparator, or subgroup is controlled.

## What would weaken this

- An independent, matched-protocol replication fails to reproduce the reported direction or magnitude.
- The contrast reverses or loses significance once the dominant confounder, comparator, or subgroup is controlled.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "2506b881-5127-4651-b21c-094d3a5f4211",
  "title": "Sglt2 inhibitors empagliflozin placebo: evidence map \u2014 7 findings across 6 sources"
}